Asparaginase Erwinia chrysanthemi

Generic Name
Asparaginase Erwinia chrysanthemi
Brand Names
Erwinaze, Rylaze, Enrylaze
Drug Type
Biotech
Chemical Formula
-
CAS Number
1349719-22-7
Unique Ingredient Identifier
D733ET3F9O
Background

Asparaginase Erwinia chrysanthemi is an asparaginase-specific enzyme derived from Erwinia chrysanthemi used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-asparaginase was first identified in 1963, and ther...

Indication

Asparaginase Erwinia chrysanthemi is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma in adults and children who have developed hypersensitivity to E. coli-derived asparaginase.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Lymphoblastic Lymphoma
Associated Therapies
-
Clinical Trials
Related News

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

First Posted Date
2017-05-23
Last Posted Date
2024-05-29
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
206
Registration Number
NCT03164057
Locations
🇺🇸

Rady Children's Hospital and Health Center, San Diego, California, United States

🇺🇸

Children's Hospital of Central California, Madera, California, United States

🇺🇸

Children's Hospital of Orange County, Orange, California, United States

and more 7 locations

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

First Posted Date
2017-04-18
Last Posted Date
2024-11-26
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
790
Registration Number
NCT03117751
Locations
🇺🇸

Children's Hospital of Michigan, Detroit, Michigan, United States

🇺🇸

St. Jude Affiliate Clinic - Novant Health Hemby Children's Hospital, Charlotte, North Carolina, United States

🇦🇺

The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia

and more 5 locations

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

First Posted Date
2017-01-13
Last Posted Date
2024-08-15
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
560
Registration Number
NCT03020030
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

🇨🇦

Hospital Sainte Justine, University of Montreal, Montreal, Quebec, Canada

and more 6 locations

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

First Posted Date
2016-12-05
Last Posted Date
2024-12-04
Lead Sponsor
Children's Oncology Group
Target Recruit Count
80
Registration Number
NCT02981628
Locations
🇺🇸

Children's Hospital of Alabama, Birmingham, Alabama, United States

🇺🇸

Providence Alaska Medical Center, Anchorage, Alaska, United States

🇺🇸

Banner Children's at Desert, Mesa, Arizona, United States

and more 153 locations

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

First Posted Date
2016-03-31
Last Posted Date
2024-11-29
Lead Sponsor
Incyte Corporation
Target Recruit Count
171
Registration Number
NCT02723994
Locations
🇺🇸

Sinai Hospital of Baltimore, Baltimore, Maryland, United States

🇺🇸

Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States

🇺🇸

Texas Childrens Hospital, Houston, Texas, United States

and more 105 locations

Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies

First Posted Date
2016-03-24
Last Posted Date
2018-06-26
Lead Sponsor
M.D. Anderson Cancer Center
Registration Number
NCT02718755

Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I

First Posted Date
2015-09-17
Last Posted Date
2024-01-18
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
50
Registration Number
NCT02553460
Locations
🇺🇸

Children's Hospital of Orange County, Orange, California, United States

🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

Rady Children's Hospital and Health Center, San Diego, California, United States

and more 14 locations

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

First Posted Date
2015-08-13
Last Posted Date
2024-11-07
Lead Sponsor
Children's Oncology Group
Target Recruit Count
280
Registration Number
NCT02521493
Locations
🇨🇦

CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL), Quebec, Canada

🇳🇿

Starship Children's Hospital, Grafton, Auckland, New Zealand

🇳🇿

Christchurch Hospital, Christchurch, New Zealand

and more 188 locations

Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies

First Posted Date
2015-04-17
Last Posted Date
2018-03-07
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
12
Registration Number
NCT02419755
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML)

Phase 1
Completed
Conditions
Acute Myeloid Leukemia
Interventions
Drug: Erwinase
First Posted Date
2014-11-05
Last Posted Date
2018-03-12
Lead Sponsor
Ashkan Emadi
Target Recruit Count
5
Registration Number
NCT02283190
Locations
🇺🇸

University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy